Company profile: Eureka Genomics
1.1 - Company Overview
Company description
- Provider of Next Generation Sequencing and gene annotation services and diagnostics to detect inherited genetic traits, cancers, and infectious diseases in humans, animals, and crops. Offerings include detection of foreign nucleic acids, sequence data analysis, resequencing and mapping, platform-agnostic genotyping of SNPs, InDels, CNV, methylation, barley and bovine SNP panels, custom NGG assay design, and NGS for CE sequencing.
Products and services
- Eureka Genotyping Solutions: Platform-agnostic NGS-based genotyping service that profiles SNPs, InDels, CNV, and methylation in various organisms, delivering standard and custom panels
- Custom NGG Assay Design: Custom-designed service engineers next-generation genotyping (NGG) assays for specific SNPs and sample sizes, tailored to client needs
- NGS for CE Sequencing: Illumina-compatible method employing NGS to produce cost-effective sequencing, enabling high-throughput sample processing for CE sequencing workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eureka Genomics
Median Technologies
HQ: France
Website
- Description: Provider of medical imaging software and services for oncology clinical trials, cancer screening, and clinical practice, standardizing and automating the interpretation of medical images to optimize diagnosis of cancer patients and assessment of their response to therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Median Technologies company profile →
Linaris
HQ: Germany
Website
- Description: Provider of a comprehensive product offering of antibodies, proteins, ELISA kits, and reagents from leading global manufacturers as a specialized distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Linaris company profile →
Isomorphic Labs
HQ: United Kingdom
Website
- Description: Provider of AI-driven drug discovery and development solutions, delivering machine-learning platforms that analyze biological data to identify drug candidates, help researchers understand complex biology, and predict compound effects. Engages in strategic collaborations with pharmaceutical companies and advances digital biology research, building on innovations like AlphaFold.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Isomorphic Labs company profile →
Lindy Biosciences
HQ: United States
Website
- Description: Provider of protein therapeutic formulation technologies, including Microglassification™ to create solid amorphous microbeads for stable long-term storage and subcutaneous delivery; high-concentration biologic formulations that reduce viscosity and increase stability for subcutaneous dosing of monoclonal antibodies; and MG Suspensions offering a subcutaneous alternative to intravenous infusions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lindy Biosciences company profile →
Tx3
HQ: United States
Website
- Description: Provider of automated quality and compliance SaaS solutions for software testing within Life Science companies, enabling agile adoption and efficient adherence to regulatory requirements such as 21 CFR Part 11. Offerings include Tricentis Tosca, qTest, NeoLoad, LiveCompare, and Data Integrity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tx3 company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eureka Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eureka Genomics
2.2 - Growth funds investing in similar companies to Eureka Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eureka Genomics
4.2 - Public trading comparable groups for Eureka Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →